

IN THE CLAIMS:

Please cancel claim 22.

Please amend claims 2, 4, 6, 9, 12, 15, and 20 as follows:

2. (Amended Three Times) The adenovirus according to claim 1, wherein the EBV antigen is EBNA 1 or EBNA2.

4. (Twice Amended) The adenovirus according to claim [1] 2, lacking regions of its genome which are required for replication in a target cell.

6. (Twice Amended) The adenovirus according to claim [1] 2, wherein the heterologous DNA sequence comprises a gene which encodes a product toxic in a cell infected by said adenovirus.

9. (Twice Amended) The adenovirus according to claim [1] 2, wherein the heterologous DNA sequence comprises a gene which encodes a product effective to inhibit cell division.

12. (Twice Amended) A composition comprising the replication defective recombinant adenovirus according to claim [1] 2 and an acceptable carrier.

15. (Amended) An isolated cell comprising the adenovirus of claim [1] 2.

20. (Amended) The adenovirus of claim [1] 2, wherein the expression signal comprises a promoter sequence from an Epstein-Barr virus [or from a human papilloma virus].

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com